Barry Templin

Mr. Templin has over 15 years of experience in clinical research, engineering, and market development, primarily within the medical device industry. Most recently, he served as the VP of Clinical Research, Engineering, and Therapy Development for CardioKinetix. Prior to CardioKinetix, Mr. Templin was the Global Clinical Program Director for Abbott Vascular. He also led the landmark vulnerable plaque natural history study, PROSPECT. Prior to that role, Mr. Templin held engineering roles with GE Aircraft Engines and Guidant, and then clinical positions with Guidant (that was later acquired by Abbott). Mr. Templin holds a BS in Mechanical Engineering and minor in Economics from Rose-Hulman Institute of Technology and an MBA from Duke.